文献速递造血干细胞移植与细胞治疗

CCR5阻断在移植物抗宿主病预防中的临床与免疫学影响

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.
PubMed 文献 · Blood · 2017-01-05

该研究比较了接受减低强度异基因造血干细胞移植并采用标准GVHD预防联合马拉韦罗(maraviroc)的患者队列与仅接受标准GVHD预防的同期对照队列。马拉韦罗治疗与急性GVHD发生率降低相关,且未增加疾病复发风险,并降低肠道特异性标志物水平;第30天时马拉韦罗增加T细胞CCR5表达并抑制T细胞活化,而未损害早期免疫重建或增加感染风险。尽管采用马拉韦罗预防仍发生急性GVHD的患者表现出T细胞活化增加、naive T细胞偏移及血清CXCL9和CXCL10水平升高。

要点

  • 马拉韦罗联合标准GVHD预防与急性GVHD发生率降低相关,且未增加疾病复发风险。
  • 马拉韦罗降低肠道特异性标志物水平,第30天增加T细胞CCR5表达并抑制T细胞活化。
  • 马拉韦罗未损害早期免疫重建或增加感染风险;突破性急性GVHD者T细胞活化增加且CXCL9/CXCL10升高。

核心结论

  • 马拉韦罗通过调节同种反应性供者T细胞反应有效预防GVHD,且CXCR3信号可能是CCR5阻断在GVHD中的重要耐药机制。

研究设计与样本

  • 比较参加减低强度异基因造血干细胞移植试验并接受标准GVHD预防联合马拉韦罗的患者队列与接受标准GVHD预防 alone 的同期对照队列。

主要发现

  • 马拉韦罗治疗与急性GVHD发生率降低相关,且未增加疾病复发风险,并降低肠道特异性标志物水平。
  • 第30天时马拉韦罗增加外周血T细胞CCR5表达并抑制T细胞活化,而未损害早期免疫重建或增加感染风险。
  • 尽管采用马拉韦罗预防仍发生急性GVHD的患者表现出T细胞活化增加、naive T细胞偏移及血清CXCL9和CXCL10水平升高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Lymphocyte trafficking via chemokine receptors such as CCR5 plays a critical role in alloreactive responses, and previous data suggest that CCR5 blockade with maraviroc results in a low incidence of visceral GVHD. However, the full scope of clinical and immunologic effects of CCR5 blockade in HSCT has not been described. We compared a cohort of patients enrolled on a trial of reduced-intensity allo-HSCT with standard GVHD prophylaxis plus maraviroc to a contemporary control cohort receiving standard GVHD prophylaxis alone. Maraviroc treatment was associated with a lower incidence of acute GVHD without increased risk of disease relapse, as well as reduced levels of gut-specific markers. At day 30, maraviroc treatment increased CCR5 expression on T cells and dampened T-cell activation in peripheral blood without impairing early immune reconstitution or increasing risk for infections. Patients who developed acute GVHD despite maraviroc prophylaxis showed increased T-cell activation, naive T-cell skewing, and elevated serum CXCL9 and CXCL10 levels. Collectively, these data suggest that maraviroc effectively protects against GVHD by modulating alloreactive donor T-cell responses, and that CXCR3 signaling may be an important resistance mechanism to CCR5 blockade in GVHD.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Moy RH, Huffman AP, Richman LP, et al. Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood. 2017. PMID: 28057639. doi:10.1182/blood-2016-08-735076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。